CureVac's COVID-19 jab did not turn out what many hoped it would be. That's despite using the same messenger RNA technology as rivals Moderna and BioNTech-Pfizer. CureVac aimed to produce its vaccine primarily for developing countries – as it can be stored more easily than other products. And despite disappointing trial-results the company is sticking to the plan.
For more news go to: www.dw.com/en/
Follow DW on social media:
Für Videos in deutscher Sprache besuchen Sie: www.youtube.com/dwdeutsch
#CureVac #Covid19 #coronavirus